Drug Metabolism and Pharmacokinetics
Online ISSN : 1880-0920
Print ISSN : 1347-4367
ISSN-L : 1347-4367

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Population Pharmacokinetic and Pharmacodynamic Analysis of Bosutinib
Poe-Hirr HsyuDiane R. MouldRichat AbbasMichael Amantea
著者情報
ジャーナル フリー 早期公開

論文ID: DMPK-13-RG-126

この記事には本公開記事があります。
詳細
抄録
 Bosutinib is an orally active, competitive inhibitor of Src/Abl tyrosine kinases. A population pharmacokinetic model was developed using data pooled from 3 studies of patients (n=870) with solid tumors or Philadelphia chromosome–positive leukemia. Patients (aged 18–91 y, weighting 35–221 kg) who received bosutinib 50 to 600 mg orally with food each contributed 6–9 pharmacokinetic samples. The final pharmacokinetic model was a linear two-compartment model with first-order absorption, an absorption lag-time, and dose-dependent bioavailability. Oral absorption was relatively slow, with a half-time of 1.14 hours and a lag-time of 0.87 hours; time to peak concentration was 5–6 hours. Apparent clearance was 120 L/h. The apparent volume of the peripheral compartment was large with a slow turnover; alpha and beta half-lives were 19 hours and 290 days, respectively. All parameters were estimated with acceptable precision (standard error <30%). No tested covariate (protocol, baseline demographic/clinical characteristics, or laboratory results) explained the high inter-individual variability of bosutinib pharmacokinetics. Therefore, adjusting bosutinib dose for body size (weight, surface area) would not provide benefit over fixed dosing. Using this exposure model in pharmacodynamic assessment of one study, adverse event incidence was shown to be similar in overall and bosutinib-responsive populations.
著者関連情報

この記事は最新の被引用情報を取得できません。

© 2014 by The Japanese Society for the Study of Xenobiotics
feedback
Top